MCMANUS MICHAEL A JR
MCMANUS MICHAEL A JR's purchase track record
How the stock did after each of MCMANUS MICHAEL A JR's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/10/2024 | UAMY | $102K | +3.6% | +111.5% | +0.1% |
| 11/18/2024 | UAMY | $28K | +221.1% | +378.9% | +1.2% |
| 8/14/2024 | UAMY | $52K | +60.5% | +405.3% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Eastern Company Backlog Growth Faces Skepticism. Recent analysis questions whether The Eastern Company's growing backlog is sufficient to support current optimism. While the firm reports increased order volume, some observers argue this may not fully justify the stock's valuation. The company trades with a trailing P/E of 19.2 and a dividend yield of 2.42%.
Transaction History
| UAMY | ▲ Buy | Grant | 6,635 | $0 | 1/15/2026 | View on chart |
| UAMY | ▼ Sell | Other | 50,000 | $366K | 10/1/2025 | View on chart |
| UAMY | ▲ Buy | Grant | 22,733 | $0 | 5/27/2025 | View on chart |
| UAMY | ▲ Buy | Open Market | 70,000 | $102K | 12/10/2024 | View on chart |
| UAMY | ▲ Buy | Open Market | 50,000 | $28K | 11/18/2024 | View on chart |
| UAMY | ▲ Buy | Open Market | 135,000 | $52K | 8/14/2024 | View on chart |
| UAMY | ▲ Buy | Grant | 83,333 | $0 | 3/1/2024 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 700 | — | 6/16/2022 | View on chart |
| EML | ▲ Buy | Grant | 763 | $19K | 12/17/2021 | View on chart |
| EML | ▲ Buy | Grant | 796 | $20K | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UAMY Dips as Rare Earth Sector Pauses Selloff
United States Antimony shares declined while peer USA Rare Earth rose 4% during a pause in a month-long selloff. This divergence highlights mixed sentiment within the critical minerals sector. The stock currently trades near its 52-week low, with an average analyst target of $10.44 remaining significantly higher than current levels.
UAMY Dips as Rare Earth Sector Pauses Selloff. United States Antimony shares declined while peer USA Rare Earth rose 4% during a pause in a month-long selloff. This divergence highlights mixed sentiment within the critical minerals sector. The stock currently trades near its 52-week low, with an average analyst target of $10.44 remaining significantly higher than current levels.